Laparoscopic Heller Myotomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laparoscopic Heller myotomy (LHM) is the gold-standard surgical treatment for achalasia, a primary oesophageal motility disorder characterised by failure of the lower oesophageal sphincter (LOS) to relax and absent peristalsis in the oesophageal body. First described in open form by Ernst Heller in 1913 and adapted to laparoscopy in the early 1990s, LHM has transformed achalasia management by combining high efficacy with the benefits of minimally invasive surgery.

The procedure involves a precise longitudinal division (myotomy) of the circular and longitudinal muscle fibres of the distal oesophagus, extending 6 cm above and at least 2 cm below the gastro-oesophageal junction (GOJ) onto the gastric cardia. This relieves the functional obstruction created by the hypertensive, non-relaxing LOS. Because complete division of the GOJ musculature abolishes the anti-reflux barrier, a partial fundoplication is routinely added to prevent pathological gastro-oesophageal reflux disease (GERD).

Achalasia is classified under the Chicago Classification version 4.0 (CCv4.0) using high-resolution manometry (HRM) into three subtypes: Type I (classic — aperistalsis with minimal pressurisation), Type II (pan-oesophageal pressurisation >20% of swallows), and Type III (spastic — premature/spastic contractions >20% of swallows). Subtype profoundly influences treatment selection. Type I and II respond well to LHM, whereas Type III achalasia shows superior outcomes with per-oral endoscopic myotomy (POEM), which can deliver a longer, more proximally extended myotomy without abdominal surgery.

Contemporary evidence from randomised controlled trials including the European Achalasia Trial and the IPONICS and LEOPOLD trials informs the current treatment algorithm, helping surgeons and gastroenterologists individualise therapy based on manometric subtype, patient age, operative risk, and centre expertise.

Laparoscopic Heller myotomy is indicated primarily for primary achalasia, but may also be considered in related oesophageal motility disorders:

• Achalasia Type I (Classic): Characterised by complete aperistalsis and a minimally pressurised oesophageal body. LHM achieves symptom relief in approximately 85% of patients at five years.
• Achalasia Type II (Pan-oesophageal pressurisation): The most common subtype, with the best overall response to any intervention — LHM success rates reach 90 – 93%. Multiple guidelines list Type II as the optimal indication for LHM.
• Achalasia Type III (Spastic/Jackhammer variant): Defined by premature contractions originating proximal to the GOJ. Standard LHM myotomy length (6 cm above GOJ) is often insufficient; a longer myotomy extending to the aortic arch is required, which is more readily performed endoscopically via POEM. Most current guidelines prefer POEM over LHM for Type III.
• Pseudo-achalasia / secondary achalasia: Occasionally caused by malignancy at the GOJ (oesophagogastric junction cancer), Chagas disease, or post-surgical stricture. Surgery is tailored to the underlying cause; primary myotomy is generally not appropriate until malignancy is excluded.
• Vigorous achalasia and diffuse oesophageal spasm (DES): In selected cases where HRM and timed barium oesophagram suggest overlapping features with achalasia, an extended myotomy may provide relief.
• Failed prior endoscopic therapy: Patients who have not achieved adequate relief after pneumatic dilation or botulinum toxin injection are appropriate surgical candidates, provided oesophageal anatomy permits safe dissection.

Careful patient selection optimises surgical outcomes and reduces the risk of complications.

Investigations required before surgery

• High-resolution manometry (HRM): Essential to confirm the diagnosis and classify the achalasia subtype per CCv4.0. Integrated relaxation pressure (IRP) above the upper limit of normal confirms impaired LOS relaxation.
• Timed barium oesophagram (TBO): Provides functional information on oesophageal emptying; column height at 1 and 5 minutes quantifies severity and serves as a post-treatment benchmark.
• Upper GI endoscopy (OGD): Mandatory to exclude pseudo-achalasia caused by GOJ malignancy, and to assess oesophageal mucosa for candidiasis or retained food.
• CT chest/abdomen: Indicated when pseudo-achalasia is suspected or when lymphadenopathy may compromise surgical access.
• Endoscopic ultrasound (EUS): Used selectively to assess submucosal tumours or intramural lesions at the GOJ.

Ideal candidates

• Confirmed primary achalasia (Type I or II) with symptomatic dysphagia, regurgitation, or weight loss
• Medically fit for general anaesthesia and laparoscopic surgery
• No prior oesophageal surgery that would preclude safe laparoscopic dissection
• Preference for durable surgical therapy over repeated endoscopic interventions

Relative contraindications

• Sigmoid oesophagus with pronounced tortuosity (may require oesophagectomy in end-stage disease)
• Morbid obesity with extreme hepatomegaly limiting surgical exposure
• Prior multiple failed myotomies with dense peri-oesophageal fibrosis
• Type III achalasia where POEM is preferred

Laparoscopic Heller myotomy is performed under general anaesthesia with the patient in a modified lithotomy (French) position or supine with reverse Trendelenburg tilt. Five ports are placed in the upper abdomen; a 30-degree angled laparoscope and specialised dissecting instruments enable precise work at the GOJ.

Key surgical steps

1. Access and exposure: Division of the gastrohepatic ligament and retraction of the left lobe of the liver expose the oesophago-gastric junction. The phreno-oesophageal membrane is incised and at least 3 cm of distal oesophagus is mobilised intra-abdominally.
2. Myotomy: Using hook electrocautery or an ultrasonic energy device, the outer longitudinal and inner circular muscle layers are divided on the anterior surface of the oesophagus. The myotomy extends 6 cm proximally onto the oesophagus and 2 – 3 cm distally onto the gastric cardia, ensuring complete division of the LOS fibres. Intraoperative endoscopy or methylene blue insufflation confirms mucosal integrity.
3. Fundoplication (anti-reflux adjunct): All contemporary LHM protocols add a partial fundoplication. Two approaches are used:
   • Dor anterior fundoplication (180°): The gastric fundus is folded anteriorly over the myotomy and sutured to the cut edges of the myotomy. It simultaneously covers the exposed mucosa, reducing the risk of mucosal perforation complications. Most widely performed globally.
   • Toupet posterior fundoplication (270°): The fundus is wrapped posteriorly around the oesophagus and sutured to the myotomy edges. Randomised trials suggest marginally superior reflux control; however, the GERD rates between Dor and Toupet are comparable in meta-analyses when added to an adequate myotomy.

Intraoperative quality checks

Intraoperative flexible endoscopy is strongly recommended to verify: (1) mucosal integrity throughout the myotomy; (2) adequacy of distal myotomy extent on the gastric cardia; and (3) absence of retained food that could increase aspiration risk. Air insufflation under saline submersion ('bubble test') identifies microperforations requiring immediate repair.

Laparoscopic Heller myotomy offers a combination of high efficacy, durability, and rapid recovery that makes it the preferred surgical treatment for most patients with achalasia.

Symptomatic relief

• Short-term success (1 year): 88 – 95% of patients report significant improvement in the Eckardt score, a validated achalasia symptom scale assessing dysphagia, regurgitation, chest pain, and weight loss.
• Long-term durability (5 – 10 years): 80 – 90% of patients maintain symptomatic remission at five years. The European Achalasia Trial (n=201, randomised LHM vs pneumatic dilation) demonstrated equivalent five-year success rates (~84%), establishing LHM as a durable alternative to pneumatic dilation for Types I and II.
• Objective oesophageal emptying: Timed barium oesophagram column height reduces by 50 – 70% at one year post-LHM, reflecting improved GOJ relaxation.

Quality of life improvements

• Significant improvement in GERD-HRQL and SF-36 quality-of-life scores
• Mean weight gain of 3 – 5 kg in malnourished patients within six months
• Resolution of aspiration pneumonia risk associated with oesophageal stasis
• Return to full diet within 4 – 6 weeks of surgery

Minimally invasive advantages

• Hospital stay 1 – 2 days versus 5 – 7 days for open Heller myotomy
• Intraoperative blood loss typically <50 mL
• Return to light activities within 2 weeks; full recovery by 4 – 6 weeks
• No large abdominal incision; 5 small port sites heal rapidly

Laparoscopic Heller myotomy is a safe procedure in experienced hands, with an overall major complication rate of 2 – 6%. Patients should be counselled on the following risks:

Intraoperative risks

• Mucosal perforation (oesophageal or gastric): The most common intraoperative complication, occurring in 2 – 8% of cases. Recognised immediately and repaired laparoscopically in the majority of cases. Unrecognised perforation can lead to life-threatening mediastinitis.
• Conversion to open surgery: Required in approximately 2 – 5% of cases, usually due to dense adhesions, obesity, or oesophageal bleeding.
• Haemorrhage: Injury to short gastric or left gastric vessels; rarely requires transfusion.

Post-operative complications

• GERD / pathological reflux: Occurs in 15 – 30% of patients without fundoplication; reduced to 8 – 15% with Dor or Toupet fundoplication. Long-term acid exposure can cause oesophagitis, Barrett's oesophagus, and stricture formation.
• Persistent or recurrent dysphagia: 10 – 20% of patients may report residual dysphagia due to incomplete myotomy, fibrosis at the myotomy site, or disease progression. Redo LHM, pneumatic dilation, or POEM can be considered.
• Fundoplication-related dysphagia: Over-tight wrap mimicking obstructive symptoms. More common after 360° Nissen than partial wraps.
• Para-oesophageal hernia: Disruption of the hiatal repair can allow stomach herniation into the chest.
• Port-site hernia: Rare (<1%), occurring at 10 mm trocar sites if fascia is not closed.

General surgical risks

Anaesthetic complications, deep vein thrombosis, pulmonary embolism, wound infection, and urinary retention apply to any abdominal surgical procedure and are mitigated by standard preventive protocols.

Structured follow-up after LHM is essential to detect early complications, monitor symptom resolution, and identify late recurrence.

Immediate post-operative care (Days 0 – 2)

• Clear liquids commenced on the day of surgery after an initial chest X-ray confirms no pneumothorax or mediastinal air
• Pureed diet from Day 1; soft diet from Day 7
• Proton pump inhibitor (PPI) therapy commenced routinely (omeprazole 20 – 40 mg daily) to protect against reflux-induced oesophagitis
• Early mobilisation to reduce DVT risk; graduated compression stockings throughout hospital stay

Short-term follow-up (Weeks 2 – 6)

• Clinical review at 2 – 4 weeks: assess Eckardt score, dietary tolerance, and wound healing
• Soft to normal diet progression by Week 4 – 6
• Avoid NSAIDs for 2 weeks post-operatively

Medium-term follow-up (3 – 12 months)

• Timed barium oesophagram at 3 – 6 months: Objective measure of oesophageal emptying improvement; column height <5 cm at 5 minutes is considered a satisfactory result
• Ambulatory 24-hour pH monitoring (6 months): Identifies pathological acid reflux in symptomatic patients; DeMeester score guides PPI dose titration
• High-resolution manometry (6 – 12 months): Assesses post-myotomy LOS pressure and can detect incomplete myotomy

Long-term monitoring

• Annual clinical review with Eckardt score assessment
• Upper GI endoscopy every 3 – 5 years to screen for Barrett's oesophagus, given the chronic acid exposure risk
• Patients with recurrent dysphagia referred for repeat HRM and TBO to determine salvage therapy

The cost of laparoscopic Heller myotomy varies considerably by country, hospital tier, and whether the procedure includes intraoperative endoscopy and fundoplication. The following ranges reflect approximate all-inclusive procedure costs (surgeon, anaesthesia, hospital stay, and standard post-operative care):

• India: USD 3,000 – 6,000 at accredited private hospitals; NABH/JCI-accredited centres in Delhi, Mumbai, Chennai, and Hyderabad offer internationally competitive outcomes
• Thailand: USD 5,000 – 9,000; internationally accredited hospitals in Bangkok (Bumrungrad, Bangkok Hospital) have dedicated upper GI programmes
• Turkey: USD 4,000 – 8,000; private hospitals in Istanbul offer combined surgical and endoscopy expertise
• United Kingdom (NHS): Funded via NHS referral; privately, GBP 8,000 – 14,000
• United States: USD 25,000 – 45,000 without insurance; most major insurance plans cover LHM for confirmed achalasia with prior conservative therapy
• Germany / Western Europe: EUR 10,000 – 18,000

Key cost drivers

• Intraoperative flexible endoscopy (typically adds USD 500 – 1,500)
• ICU admission if mucosal perforation repaired intraoperatively
• Post-operative ambulatory pH monitoring and HRM studies
• Duration of hospital stay and geographic location
• Surgeon and centre experience (specialist oesophageal centres may command higher fees but deliver lower complication rates)

International patients should request itemised quotes covering all pre-operative investigations, surgical fees, anaesthesia, hospital stay, and a defined post-operative review period.

Several non-surgical and endoscopic alternatives to LHM exist. The optimal choice depends on achalasia subtype, patient age and fitness, centre expertise, and patient preference. A multidisciplinary team discussion — involving a gastroenterologist, oesophageal surgeon, and radiologist — is recommended before committing to any modality.

Per-oral endoscopic myotomy (POEM)

POEM is an advanced endoscopic procedure in which a submucosal tunnel is created from the mid-oesophagus to the gastric cardia, and the circular muscle layer is divided under endoscopic vision without abdominal incisions. It is equivalent to LHM for Types I and II, but superior for Type III achalasia (spastic subtype) because the myotomy can be extended more proximally without additional technical complexity. The IPONICS trial (2021, n=133) and LEOPOLD trial (2022) both confirmed POEM superiority for Type III in terms of post-operative Eckardt score and IRP reduction. The main disadvantage of POEM is a higher post-operative GERD rate (approximately 40 – 60%) compared to LHM with fundoplication (8 – 15%), as no anti-reflux procedure accompanies POEM.

Pneumatic dilation (PD)

Endoscopic balloon dilation of the LOS using graded Rigiflex balloons (30, 35, or 40 mm) disrupts the sphincter muscle fibres without surgery. The European Achalasia Trial demonstrated equivalent five-year outcomes to LHM for Types I and II (~84% success). Multiple sessions may be required. The major risk is oesophageal perforation (1 – 5%), which may require emergency surgery. PD is preferred in elderly or high-surgical-risk patients and serves as a bridge or maintenance therapy.

Botulinum toxin injection

Endoscopic injection of botulinum toxin A into the LOS (typically 80 – 100 units) inhibits acetylcholine release and temporarily reduces sphincter pressure. Relief lasts 6 – 12 months in 50 – 70% of patients, with diminishing efficacy after repeated injections due to scar formation. Reserved for patients unfit for surgery or dilation, or as a diagnostic trial. Repeated injections may complicate subsequent LHM by inducing submucosal fibrosis.

Oesophagectomy

Reserved for end-stage achalasia with sigmoid oesophagus deformity, repeated failed myotomies, or high-grade dysplasia/carcinoma in situ. A major procedure with 2 – 5% mortality in specialist centres.